Alexey Larionov Resistance to Aromatase Inhibitors in Breast Cancer 9783319179711

Варианты приобретения

Цена: 19564.00р.
Кол-во:
Наличие: Поставка под заказ. Есть в наличии на складе поставщика.
Склад Америка: Есть
При оформлении заказа до: 2025-07-28
Ориентировочная дата поставки: Август-начало Сентября
При условии наличия книги у поставщика.

Добавить в корзину

в Мои желания

Автор: Alexey Larionov
Название: Resistance to Aromatase Inhibitors in Breast Cancer
ISBN: 9783319179711
Издательство: Springer
Классификация:

Медицинское оборудования и методики его эксплуатации

Медицинские исследования

Анатомия

Онкология

Фармакология

ISBN-10: 3319179713
Обложка/Формат: Hardcover
Страницы: 288
Вес: 0.62 кг.
Дата издания: 05.05.2015
Серия: Resistance to Targeted Anti-Cancer Therapeutics
Язык: English
Издание: 2015 ed.
Иллюстрации: 16 tables, black and white; 27 illustrations, color; 29 illustrations, black and white; xvi, 288 p. 56 illus., 27 illus. in color.
Размер: 234 x 156 x 19
Читательская аудитория: Professional & vocational
Основная тема: Cancer Research
Ссылка на Издательство: Link
Рейтинг:
Поставляется из: Германии
Описание: Aromatase Inhibitors (AIs) treat postmenopausal estrogen receptor positive tumours, which constitute the majority of breast cancer patients. This comprehensive volume brings together the current knowledge from different relevant areas, including molecular mechanisms and translational aspects of drug resistance in AIs. Topics covered include research, experimental , and clinical data specifically focused on AI resistance in breast cancer. The volume will include three sections. The first section covers general knowledge about aromatase inhibitors, including regulation of aromatase genes, and structure and function of aromatase protein. The second section provides the detailed mechanisms of resistance to AIs, while the third section explores prediction of resistance and potential strategies to overcome resistance. Breast cancer is the most common female cancer and AIs significantly improve treatments outcomes compatibly to previously used endocrine treatments. However 10-15% of post-operative patients develop a relapse during adjuvant treatment with AIs; about 25-50% of the patients do not respond to AIs in neo-adjuvant or metastatic setting, and the majority of metastatic patients who initially respond develop resistance within 3 years. There is an important need to understand these mechanisms of resistance in order to develop methods of preventing or overcoming the resistance to AIs, which will ensure a more successful outcome in treating breast cancer.
Дополнительное описание: 1 Clinical Use of Aromatase Inhibitors in Breast Cancer: History and Present.-2 Structure, Regulation and Polymorphisms of the Aromatase Gene .-3 Structure, Function and Inhibition of Aromatase.-4 In Vivo Models of AI Resistance.-5 Ineffective inhibition

Resistance to Aromatase Inhibitors in Breast Cancer, Alexey Larionov